Literature DB >> 11099773

Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task.

A J Grottick1, G A Higgins.   

Abstract

Nicotine can improve attentional functioning in humans, and a number of studies have recently demonstrated that under specific task conditions, nicotine can also improve attention in the rat. Neuronal nicotinic receptors comprise combinations of alpha(2-9) and beta(2-4) subunits, arranged to form a pentameric receptor, with the principal CNS subtypes currently believed to be alpha(4)beta(2) and a homomeric alpha(7) receptor. In the present studies, we attempted to delineate the particular nicotinic receptor subtype(s) contributing to the effects of nicotine on attention by assessing various nicotinic ligands on performance in the five-choice serial reaction time task (5-CSRTT). In rats performing below criterion (<80% correct, >20% omissions to a 1-s visual stimulus), subchronic dosing with nicotine (0.2 mg/kg sc) and the alpha(4)beta(2) agonist SIB 1765F (5 mg/kg sc) increased correct responding and decreased response latencies across the treatment week; whereas the alpha(7) agonist AR-R 17779 (20 mg/kg sc) was without effect. In subjects meeting the criterion, the competitive high affinity (including alpha(4)beta(2)) nicotine receptor antagonist DHbetaE (1-10 mg/kg sc) and the alpha(7) antagonist methyllycaconitine (MLA: 5-10 mg/kg i.p.) did not disrupt performance, whereas at the highest dose, the non-competitive antagonist mecamylamine (0.3-3 mg/kg sc) decreased accuracy and increased response latencies. These changes bore some similarities to those of pre-feeding and the non-competitive NMDA antagonist dizocilpine (0.03-0.06 mg/kg sc), suggesting that mecamylamine-induced performance disruption may relate to non-nicotinic receptor effects. In subjects chronically treated with nicotine, acute nicotine challenge (0.4 mg/kg sc) significantly increased accuracy whilst having no effect on any other performance measures. Finally, in these same nicotine pre-treated rats, the decrease in latency and increase in premature responses induced by nicotine (0.2 mg/kg sc) to a target stimulus of 150 ms was fully antagonised by DHbetaE (3 mg/kg sc) but not MLA (5 mg/kg i.p.). These results suggest that alpha(7) receptors do not play a role in any of the behavioural effects of nicotine observed in the 5-CSRTT, whereas a high affinity site, perhaps alpha(4)beta(2), is more likely involved.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11099773     DOI: 10.1016/s0166-4328(00)00305-3

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  96 in total

1.  Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague-Dawley rats.

Authors:  Amir H Rezvani; Marty Cauley; Hannah Sexton; Yingxian Xiao; Milton L Brown; Mikell A Paige; Brian E McDowell; Kenneth J Kellar; Edward D Levin
Journal:  Psychopharmacology (Berl)       Date:  2011-01-28       Impact factor: 4.530

Review 2.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Nicotine Addiction and Psychiatric Disorders.

Authors:  Munir Gunes Kutlu; Vinay Parikh; Thomas J Gould
Journal:  Int Rev Neurobiol       Date:  2015-09-19       Impact factor: 3.230

4.  Strain dependency of the effects of nicotine and mecamylamine in a rat model of attention.

Authors:  Britta Hahn; Katelyn E Riegger; Greg I Elmer
Journal:  Psychopharmacology (Berl)       Date:  2016-02-15       Impact factor: 4.530

5.  Forebrain deletion of the vesicular acetylcholine transporter results in deficits in executive function, metabolic, and RNA splicing abnormalities in the prefrontal cortex.

Authors:  Benjamin Kolisnyk; Mohammed A Al-Onaizi; Pedro H F Hirata; Monica S Guzman; Simona Nikolova; Shahar Barbash; Hermona Soreq; Robert Bartha; Marco A M Prado; Vania F Prado
Journal:  J Neurosci       Date:  2013-09-11       Impact factor: 6.167

6.  Differential control of central cardiorespiratory interactions by hypercapnia and the effect of prenatal nicotine.

Authors:  Zheng-Gui Huang; Kathleen J S Griffioen; Xin Wang; Olga Dergacheva; Harriet Kamendi; Christopher Gorini; Euguenia Bouairi; David Mendelowitz
Journal:  J Neurosci       Date:  2006-01-04       Impact factor: 6.167

7.  A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHD.

Authors:  Earle E Bain; Weining Robieson; Yili Pritchett; Tushar Garimella; Walid Abi-Saab; George Apostol; James J McGough; Mario D Saltarelli
Journal:  Neuropsychopharmacology       Date:  2012-10-03       Impact factor: 7.853

Review 8.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

Review 9.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

10.  Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat.

Authors:  Guy A Higgins; Theresa M Ballard; Michel Enderlin; Marie Haman; John A Kemp
Journal:  Psychopharmacology (Berl)       Date:  2005-03-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.